Health and Healthcare
Depomed Tumbles on Missed Earnings
Published:
Last Updated:
When Depomed Inc. (NASDAQ: DEPO) reported its third-quarter financial results after the markets closed on Monday, it posted $0.28 in earnings per share (EPS) and $110.5 million in revenue. The consensus estimates from Thomson Reuters had called for $0.35 in EPS and revenue of $127.22 million. The same period of last year reportedly had EPS of $0.33 and $104.86 million in revenue.
During this quarter, a settlement agreement was reached with activist firm Starboard Value regarding the inclusion of three additional independent directors — James P. Fogarty, Robert G. Savage and James L. Tyree — to Depomed’s board of directors.
Nucynta products had net sales of $65.29 million, also recording an all-time monthly high prescription volume of over 30,000 in August. Gralise third-quarter net sales totaled $21 million and Cambia net sales were a record $9.1 million, an increase of 29% compared to $7 million in the same period last year. Finally, Lazanda net sales were a record $8.2 million, an increase of 50% compared to $5.4 million in the same period last year.
On the books, Depomed cash, cash equivalents and marketable securities totaled $137.09 million at the end of the quarter, versus $209.77 million at the end of 2015.
Jim Schoeneck, president and chief executive of Depomed, commented:
Although our third quarter revenues increased by 5% over the previous year’s quarter, they did not meet our expectations, as several factors, including a disconnect between prescription demand and wholesaler shipments, influenced net sales of the NUCYNTA franchise and Gralise. Prescriptions for NUCYNTA ER grew 4% over the second quarter, while shipments to wholesalers were down 1%. Prescriptions for NUCYNTA and Gralise were equal to the second quarter, however, shipments were down 6% and 12%, respectively. In addition, we made adjustments to our reserve accounts, including managed care and PBM rebate submissions from prior quarters, which impacted our product net sales.
Shares of Depomed were last seen down 20.5% at $18.20 on Tuesday, with a consensus analyst price target of $26.27 and a 52-week trading range of $12.25 to $27.02.
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
